A large-scale, placebo-controlled clinical study shows a remarkable benefit from adding exenatide, a short-acting GLP-1 receptor agonist, to insulin glargine, on a background of metformin and/or pioglitazone, in patients with type 2 diabetes mellitus. Is this partnership here to stay?
- Michael A. Nauck
- Juris J. Meier